Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials

Charity J. Morgan, William K. Oh, Gurudatta Naik, Matthew D. Galsky, Guru Sonpavde

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations

Abstract

We conducted a meta-analysis of randomized trials comparing regimens that included daily oral prednisone (P) in only one arm to investigate its impact on toxicities and outcomes in metastatic castration-resistant prostate cancer (mCRPC). Five trials were identified totaling 2939 patients, of whom 1471 were randomized to an arm not containing P and 1468 received therapy containing P. There was no difference between the non-P and P groups for severe toxicities (incidence rate ratio [IRR]=0.82, p=0.712, I2=97.9%). When examining toxicities as a reason for discontinuing therapy, the non-P groups were not different from the P groups (relative risk [RR]=1.24, p=0.413, I2=86.8%). The non-P groups demonstrated no difference in OS compared to the P groups (HR=1.09, p=0.531, I2=79.7%). The meta-analysis is limited by the trial level design and small number of trials.

Original languageEnglish
Pages (from-to)253-261
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume90
Issue number3
DOIs
StatePublished - Jun 2014
Externally publishedYes

Keywords

  • Clinical trial
  • Meta-analysis
  • Metastatic castration-resistant prostate cancer
  • Prednisone
  • Randomized
  • Survival
  • Toxicities

Fingerprint

Dive into the research topics of 'Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials'. Together they form a unique fingerprint.

Cite this